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INTRODUCTION
Diabetes mellitus and prediabetes are becoming serious public health problems in the world. Moreover, cardiovascular disease (CVD) is the most leading cause of death and the major complication of type 2 diabetes mellitus (T2DM) and prediabetes (1) . It has been demonstrated that impaired insulin metabolism predisposes individuals at risk of type 2 diabetes to CVD through dyslipidemia. So, the alteration in plasma lipid and lipoprotein profile has been strongly documented in diabetic and pre-diabetic patients (2) . The central goal in CVD prevention and treatment is reducing the levels of serum cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides as well as increasing in high-density lipoprotein (HDL) cholesterol (3) . The pathogenesis of type 2 diabetes and cardiovascular diseases involves both genetic and environmental factors (4, 5) , among which gut microbiota as a new approach, play an important role (6, 7) . The association between gut microbiota and diseases has been set forth the demand for new functional products (8) . It is suggested that consumption of probiotics and/or prebiotics as the functional foods would be a good approach for this meaning (9) . Probiotics are live microorganisms that when administered in adequate amounts could confer a health benefit on the host (10, 11) . The most two commonly used groups of probiotic bacteria, are Lactobacillus and Bifidobacterium (12) . Some studies indicated that probiotics may be able to decrease the levels of total cholesterol (TC), LDL-c and balance the ratio of LDL-c/HDL-c (13) .
Prebiotics are non-digestible oligosaccharides that their use as the food ingredients on health has been recently triggered much research. Among other beneficial effects of prebiotics, the blood lipid reduction is of particular interest (14) . Synbiotic that contains both probiotics and prebiotics is used to effectively modulate gut microbiota and the health benefit can be synergistic. The beneficial effects of synbiotic could be via mechanisms such as gut hormone balance, energy storage and dietary energy expenditure, production of short chain fatty acids (SCFA), and improvement in immune function and insulin resistance (15) .
Therefore, it is hypothesized that supplementation with probiotic or prebiotic or synbiotic might be effective on the lipid and lipoprotein profile improvement. Understanding the role of probiotics or synbiotics on lipid profiles may provide ideas for new prevention and treatment strategies in cardiovascular disease and the other complications of diabetes and prediabetes.
However, there is the contradiction about this conception in previous studies (16) . In view of the limited number of high-quality clinical trials in this regard and the contradictory results, the present study was designed to investigate and compare the effects of probiotics and synbiotic supplementation on lipid and lipoprotein profiles in pre-diabetic patients in a double blind randomized controlled parallel groups clinical trial.
MATERIALS AND METHODS

Participants
The participants with prediabetes were selected from the first-degree relatives of type 2 diabetic patients in Isfahan Endocrine and Metabolism Research Center outpatient clinic, Iran.
Diagnosis of prediabetes was based on the criteria of American Diabetes Association (17); those with one of the following criteria: fasting plasma glucose (FPG) 100-125 mg/dl and/or blood sugar (BS) 2-h pp 140-199 mg/dl via oral glucose tolerance test (OGTT). Individuals (men and women) aged 35 to 70 years old with the above-mentioned inclusion criteria were called to participate in the study.
The exclusion criteria were suspected or definite history of alcohol or drug abuse, currently smoking, using probiotic, prebiotic or synbiotic during the past 3 months, antibiotic or laxatives use in the past 3 months or during the study, pregnancy, having food allergies, celiac or irritable bowel disease, having severe liver, kidney, heart or nervous system diseases, currently taking nonsteroidal anti-inflammatory drugs, antipsychotics, or nicotinic acid. If a participant missed more than 10 percent of supplement dose (defined to non-compliance) or had irritable or any kind of allergy to studied agents, he or she excluded from the study at any stage of the investigation. Also, the participants were excluded from the study if there was any change in medication, modify in lifestyle or start antibiotics at any stage of the investigation.
Study Design
The study was a randomized, double-blind, placebo-controlled, three-arms, and parallel-group clinical trial on prediabetic subjects which was designed according to the CONSORT 2010 and SPIRIT 2013 guidelines (18) . The participants were randomly assigned into three equal groups to receive either probiotic or synbiotic or placebo for 6 months using block stratified randomization method (stratified for gender and age). The randomization list was provided by a person who not involved in the study using numbered containers to implement the random allocation sequence. Investigators, participants, and laboratory staff were blinded to the allocation of the three supplements. The appearance and packaging of the three products were identical. The blinding code was provided to the investigators after completing the statistical analyses.
The participants advised not to modify daily dietary and physical activity habits during the study period. To ensure that these habits had not been modified during the study, the participants were instructed to record 3 days' food and physical activity diaries and checked by a dietitian at the baseline and follow-ups.
Also, the participants were advised not to modify their medication during the experiment. Adherence to treatment was assessed by weekly phone calls, during regularly scheduled appointments, and by returned sachet counts. Time schedule of enrolment, interventions, assessments, and visits for participants has been shown in table 1.
Table 1. Time schedule of enrolment, interventions, assessments, and visits for participants
Time Visits and Activities
Prior to starting the study The patients who have eligibility criteria were asked to read and sign the consent form. The patients were instructed on writing the food and physical activity records. They were asked not to give any other dietary supplementation and not to change their medication and/or life style during the study and to inform the investigators if they had been prescribed oral antibiotics at any time during the study.
Start of study
Food and physical activity records were collected. Weight and height were measured. Lipid profile tests were performed. The supplements were delivered.
Week 2, 4, 9
Contacted with the participants and effectiveness or adverse events were recorded.
Week 12
Week 14, 16, 18, 20 Contacted with the participants and effectiveness or adverse events were recorded.
Week 24
Food and physical activity records were collected. Weight and height were measured. Lipid profile tests were performed.
Ethics statements
The study protocol was conducted according to the principles expressed in the Declaration of Helsinki and has been approved by the Ethics Committee of Isfahan University of Medical Sciences (approval number: IR.MUI.REC.1394.3.813). The trial has been registered at Iranian Registry of Clinical Trials as IRCT201511032321N2.The purpose of the study, benefits or side effects of the supplements were fully explained to all participants and written informed consent was obtained prior to the commencement of study. The personal information of enrolled participants was collected via encoding procedures.
Intervention
The participants were instructed to consistently take 6 grams of the supplements diluted in a cup of water and drink it each day after main meal (lunch or dinner) to minimize the killing of the probiotic by gastric acid for 6 months.
The probiotic sachet contained the freeze-dried Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium lactis, and Bifidobacterium longum (1.5×10 9 CFU for each) with maltodextrin as the filler. Synbiotic comprised the above-mentioned probiotics plus inulin as prebiotic and placebo included maltodextrin. The synbiotic was designed in the present study for the first time in Iran. All of the microbial and purity tests had been checked by two independent microbiologists and the solubility and palatability of supplements had been assessed to determine the optimal well-tolerated mode of delivery of the supplement prescription. The supplements were prepared and packaged in Tak Gen Zist Pharmaceutical Company, Tehran, Iran.
Biochemical assessments
Fasting blood samples (10 mL) were taken at baseline and after 3 and 6 months of intervention at the Isfahan Endocrine and Metabolism Research Center laboratory in the early morning after 12
hours overnight fast. The participants were instructed not to do vigorous physical activity for the previous 48 hours. Plasma lipids and lipoproteins concentrations (i.e., triglycerides, total cholesterol, and high-and low-density lipoprotein cholesterol) were measured using a photometric assay kit (Pars Azmoon Co., Tehran, Iran).
Anthropometric measurements
Height and weight were measured at baseline and repeated at months 3 and 6.
Height was determined using a scale-mounted stadiometer to the nearest 0.5 cm and weight was measured with light clothing to the nearest 0.1 kg. BMI was calculated by dividing weight in kilograms by squared height in meters. All of the measurements were taken by a trained nutritionist to decrease the error rate. Furthermore, the nutritionist was blinded to the randomization assignments.
Food Intake and Physical Activity Assessments
Participants were instructed to record their daily food and beverage intake for 3 days (2 weekdays and one weekend) at baseline, 3 months and 6 months of the intervention period. The records were analyzed for energy content and macro nutrients (carbohydrate, protein and fat) using Nutritionist IV software (First Databank, San Bruno, CA). Physical activity records were assessed using the metabolic equivalent of task (MET) questionnaire. To measure the METs for each participant, the times (in hour per day) reported for each physical activity was multiplied by its related METs coefficient via standard tables (19) .
Statistical Analysis
Sample size calculation was based on a parallel three-group randomized clinical trial with repeated 
RESULTS
A total of 224 prediabetic individuals (152 females and 72 males) were called to enter the study.
Among them 104 subjects were excluded because they declined to participate or did not fulfilling the inclusion criteria. From 120 individuals who were participated and randomly assigned into the three study groups, 30 participants were dropped out before the first 3 months and 5 ones between 3 and 6 months of the intervention period because of using antibiotic during the study, low compliance, disinclination, GI complications, and traveling. Finally, the data for 85 participants who had completed the 6-months' intervention (27 in probiotic, 30 in synbiotic and 28 in placebo groups) were analyzed. Screening, enrollment, and retention of the participants are shown in Figure 1 . There were no statistically significant differences between the groups whom completed interventions and the lost to follow-up/discontinued in baseline lipid profiles and anthropometric measures ( Table 2 ). The included participants (the participants who completed study period) were 38 males (45%) and 47 females (55%) with the mean age 52.95±6.3 years. No statistically significant differences were found in baseline characteristics between the probiotics, synbiotic or placebo groups ( Table 3 ). The food intakes, physical activity, and anthropometric measures were not different between the probiotics, synbiotic or placebo groups at baseline and remained unchanged during the study (Table 4 ). 0.41 0.37 0.82 p-value * Resulted from Repeated Measured ANOVA for comparing the changes over time within and between study groups ** Resulted from ANOVA for comparing the changes at each time between study groups A repeated measures ANOVA with a Greenhouse-Geisser correction determined that total cholesterol, LDL-c, and HDL-c were changed neither within nor between the three groups during the study period. However, mean triglyceride levels decreased significantly in probiotic and synbiotic groups and significantly increased in the placebo group after 6 months of intervention. Post-hoc Bonferroni correction for multiple comparisons revealed that the differences between synbiotic group and placebo group have been statistically significant (Table 5 ). No serious adverse events were reported by the participants during the study. The only adverse event which has been reported by 12 subjects was mild gastrointestinal complication (2 in the probiotic group, 6 in the synbiotic group and 4 in the placebo group, P=0.32). Table 5 . Lipid profiles at the baseline and after 3 and 6 months of intervention in probiotic, symbiotic and placebo group. a Resulted from Repeated Measured ANOVA for comparing the changes over time between study groups *OP: Observed Power **G1= Probiotic group, G2= Synbiotic group, G3= Placebo group
DISCUSSION
A number of studies have been conducted to investigate the role of probiotics and/or prebiotics in lipid metabolism. Among them, in vitro studies and animal model researches have supported the hypolipidemic effect of probiotics (20) . However, human clinical studies have yielded mixed results (21, 22) .
Up to know, we have not enough documents about the effects of synbiotics on lipid profiles in individuals with prediabetes who are at risk of diabetes mellitus and cardiovascular diseases. The current study demonstrated that consumption of synbiotic supplement in prediabetic individuals for 6 months resulted in a decrease in serum triglyceride levels compared to placebo. Previous animal studies have shown that the gut microbiome may play an important role in serum lipids, supporting the potential of therapies altering the gut microbiome to control triglycerides (23, 24) . In a previous study by Liong MT et.al (25) the use of a synbiotic food containing Lactobacillus.acidophilus, FOS, inulin, and mannitol has been resulted in decreased serum triglycerides, total cholesterol and LDL-C levels and increased concentrations of HDL-cholesterol in hyper-cholesterolemic pigs after 8 weeks. The mechanisms which have been proposed for triglyceride lowering effect by synbiotics may be lipolysis of triglycerides, suppressing the NF-κB pathway, gut microbiota-SCFA-hormone axis and de-conjugation of intestinal bile salts by bacterial bile salt hydrolase. The influence on TLR4 signaling and pro-inflammatory cytokines might also explain lipid-lowering effects of probiotics and prebiotics (26, 27) . It is demonstrated that an elevated HDL cholesterol level and decreased in total and LDL-cholesterol are generally regarded as the factors reducing the risk of cardiovascular disease and as the protective factors in diabetes mellitus (20, 28) . However, our study did not show a significant effect of probiotics or synbiotic on HDL cholesterol levels, total cholesterol and LDL-cholesterol profiles. This result confirms the recent meta-analysis on diabetic patients by Kecheng Yao et al (16) which concluded that the effects of probiotics on cholesterol levels and lipid metabolism are not convincing. Generally, the reports on the association between lipid parameters and probiotic or synbiotic consumption are inconsistent (29, 30) which these discrepancies may have been caused by using various probiotic strains, the characteristics of the study population groups, differences in experimental designs, and the length of intervention. It seems that using high-dose multispecies probiotic may be more effective than single-strain. Probiotics in a multi-species compete with each other and create their own mini-ecosystem which forces antagonistic species to strengthen their defense mechanisms (29) . Overall, strong clinical trials are still very limited in this field and more studies are needed to determine the true relationship between probiotic or synbiotic supplementation and cardio metabolic risk factors.
Limitation
Because of long duration of intervention, we had more attrition rate than we had expected in the protocol. So, we used a post-power analysis to cover this limitation.
CONCLUSIONS
The results of this study showed that 6 months oral supplementation with probiotics and particularly synbiotic decreased the concentration of triglyceride in prediabetic subjects. This finding could warrant future studies to determine the therapeutic and preventive effects of these supplements in individuals at risk of diabetes and cardiovascular diseases. Our findings do not suggest that probiotics or synbiotic are an effective means to favorably affect serum cholesterols. However, it remains possible that other types of prebiotics or strains of probiotics, with different dose patterns, do affect serum cholesterol concentrations. Overall, human interventions of synbiotic and probiotic showed mixed findings on lipid profiles and further works are required.
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